- Institute for Reproductive Health
- United States of America
We and selected partners, use cookies or similar technologies as specified in the cookie policy and privacy policy.
You can consent to the use of such technologies by closing this notice.
Customise your preferences for any tracking technology
The following allows you to customize your consent preferences for any tracking technology used to help us achieve the features and activities described below. To learn more about how these trackers help us and how they work, refer to the cookie policy. You may review and change your preferences at any time.
These trackers are used for activities that are strictly necessary to operate or deliver the service you requested from us and, therefore, do not require you to consent.
These trackers help us to deliver personalized marketing content and to operate, serve and track ads.
These trackers help us to deliver personalized marketing content to you based on your behaviour and to operate, serve and track social advertising.
These trackers help us to measure traffic and analyze your behaviour with the goal of improving our service.
These trackers help us to provide a personalized user experience by improving the quality of your preference management options, and by enabling the interaction with external networks and platforms.
Recent Comments
Interesting article. I think the issue with the vaginal progesterone group is that it was not given long enough and at enough dosage. We transfer of the 6th day of progesterone and use endometrin tid.
Our live birth rates for 2014 and 2015 without the use of PGS are greater than the clinical pregnancy rates you report.
Age LBR N
<35 42.6% 357
35-37 37.4% 115
38-40 39.1% 46
I realize this is an interim report and maybe I did not read closely enough but I did not see data on mean age of patients or implantation.
Sherif G Awadalla, M. D.
Institute for Reproductive Health
Cincinnati, OH